Biopharmaceutical company TNF Pharmaceuticals Inc (Nasdaq: TNFA) announced on Wednesday that it presented its oral TNF-alpha inhibitor isomyosamine during a platform presentation titled "Isomyosamine for the Treatment of Sarcopenia in Older Adults" at the British Geriatrics Society Spring Meeting, held 09–11 April 2025 in Belfast, Ireland and online.

Mitchell Glass, MD, President and Chief Medical Officer, outlined positive clinical data that validate the start of a larger Phase 2b trial in elderly patients post-hip fracture.

Data indicate that isomyosamine decreases biomarkers associated with TNF-alpha activation in elderly patients with sarcopenia.

Glass reaffirmed the company's commitment to addressing sarcopenia, including muscle wasting associated with GLP-1 agonist treatments, and noted plans to extend Phase 3 trials into the UK and Europe.

Isomyosamine, a novel plant alkaloid (ICD-10-CM code M62.84), regulates the immuno-metabolic system by modulating pro-inflammatory cytokines such as TNF-alpha. TNF Pharmaceuticals remains dedicated to developing innovative therapies that extend healthy lifespan and address autoimmune and inflammatory conditions.